Phase 3 Trial Shows Peanut Patch Treatment Helps Toddlers Build Tolerance To Deadly Allergy

Phase 3 Trial Shows Peanut Patch Treatment Helps Toddlers Build Tolerance To Deadly Allergy

Phase 3 Trial Shows Peanut Patch Treatment Helps Toddlers Build Tolerance To Deadly Allergy Maryam Sicard for Unsplash+ Toddlers safely built a tolerance to small amounts of peanut proteins thanks to a simple skin patch, which helped prevent the progression of a potentially deadly allergy. More than 70% of these toddlers could tolerate 3 or 4 peanut kernels after a 3-year course of treatment, say American scientists working to commercialize the skin patch. The findings, from an FDA-registered, long-term, phase 3 clinical trial offer encouraging news for parents of the one child in 50 born every year with the susceptibility to peanut allergies. The study found that a peanut patch treatment—called epicutaneous immunotherapy, or EPIT—continued to help toddlers safely build tolerance to peanuts over three years. It used the DBV Technologies Viaskin Peanut Patch, which delivers small amounts of peanut protein through the skin. The goal is to train the immune system to tolerate peanut exposure an…